Eligo Publishes in Nature a Landmark Study That Unlocks Genome Editing of Bacteria in the Gut

"What Eligo has achieved shows that it's now possible to make specific changes to the DNA of bacteria in the gut, similar to how scientists have been editing human genes to investigate or treat genetic disorders," said David Bikard, cofounder of Eligo Bioscience and researcher at the Institut Pasteur in Paris. "What Eligo has achieved shows that it's now possible to make specific changes to the DNA of bacteria in the gut, similar to how scientists have been editing human genes to investigate...

PARIS, 10/07/2024 (informazione.it - comunicati stampa - salute e benessere)

" said David Bikard, cofounder of Eligo Bioscience and researcher at the Institut Pasteur in Paris .

Eligo demonstrated the ability to engineer a bacteriophage-derived capsid containing a synthetic DNA payload encoding a base-editor system. After oral administration to mice, the capsid delivered the payload with extreme efficiency to target bacterial populations residing among the hundreds of bacterial species in the mouse gut. Remarkably, the system could precisely inactivate antibiotic resistance genes by creating single-base pair mutations in the corresponding genes. When targeting strains, the technology modified the target gene in over 90% of the bacteria, reaching up to 99.7% in some cases.

Jesus Fernandez, Eligo VP of Technology and a senior author of the study, highlights how "

Eligo is pioneering in microbiome in-vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in immuno-inflammation, oncology, and infectious diseases.

For more information:  https://eligo.bio/

Contact: DUPORTET Xavier; xavier.duportet@eligo-bioscience.com

View original content: https://www.prnewswire.co.uk/news-releases/eligo-publishes-in-nature-a-landmark-study-that-unlocks-genome-editing-of-bacteria-in-the-gut-302193679.html